Impact of socioeconomic status on survival for patients with anal cancer

BACKGROUND

Although outcomes for patients with squamous cell carcinoma of the anus (SCCA) have improved, the gains in benefit may not be shared uniformly among patients of disparate socioeconomic status. In the current study, the authors investigated whether area-based median household income (MHI) is predictive of survival among patients with SCCA.

METHODS

Patients diagnosed with SCCA from 2004 through 2013 in the Surveillance, Epidemiology, and End Results registry were included. Socioeconomic status was defined by census-tract MHI level and divided into quintiles. Multivariable Cox proportional hazards models and logistic regression were used to study predictors of survival and radiotherapy receipt.

RESULTS

A total of 9550 cases of SCCA were included. The median age of the patients was 58 years, 63% were female, 85% were white, and 38% were married. In multivariable analyses, patients living in areas with lower MHI were found to have worse overall survival and cancer-specific survival (CSS) compared with those in the highest income areas. Mortality hazard ratios for lowest to highest income were 1.32 (95% confidence interval [95% CI], 1.18-1.49), 1.31 (95% CI, 1.16-1.48), 1.19 (95% CI, 1.06-1.34), and 1.16 (95% CI, 1.03-1.30). The hazard ratios for CSS similarly ranged from 1.34 to 1.22 for lowest to highest income. Older age, black race, male sex, unmarried marital status, an earlier year of diagnosis, higher tumor grade, and later American Joint Committee on Cancer stage of disease also were associated with worse CSS. Income was not found to be associated with the odds of initiating radiotherapy in multivariable analysis (odds ratio of 0.87 for lowest to highest income level; 95% CI, 0.63-1.20).

CONCLUSIONS

MHI appears to independently predict CSS and overall survival in patients with SCCA. Black race was found to remain a predictor of SCCA survival despite controlling for income. Further study is needed to understand the mechanisms by which socioeconomic inequalities affect cancer care and outcomes. Cancer 2018. © 2018 American Cancer Society.

http://ift.tt/2HpgZFZ

Impact of socioeconomic status on survival for patients with anal cancer

BACKGROUND

Although outcomes for patients with squamous cell carcinoma of the anus (SCCA) have improved, the gains in benefit may not be shared uniformly among patients of disparate socioeconomic status. In the current study, the authors investigated whether area-based median household income (MHI) is predictive of survival among patients with SCCA.

METHODS

Patients diagnosed with SCCA from 2004 through 2013 in the Surveillance, Epidemiology, and End Results registry were included. Socioeconomic status was defined by census-tract MHI level and divided into quintiles. Multivariable Cox proportional hazards models and logistic regression were used to study predictors of survival and radiotherapy receipt.

RESULTS

A total of 9550 cases of SCCA were included. The median age of the patients was 58 years, 63% were female, 85% were white, and 38% were married. In multivariable analyses, patients living in areas with lower MHI were found to have worse overall survival and cancer-specific survival (CSS) compared with those in the highest income areas. Mortality hazard ratios for lowest to highest income were 1.32 (95% confidence interval [95% CI], 1.18-1.49), 1.31 (95% CI, 1.16-1.48), 1.19 (95% CI, 1.06-1.34), and 1.16 (95% CI, 1.03-1.30). The hazard ratios for CSS similarly ranged from 1.34 to 1.22 for lowest to highest income. Older age, black race, male sex, unmarried marital status, an earlier year of diagnosis, higher tumor grade, and later American Joint Committee on Cancer stage of disease also were associated with worse CSS. Income was not found to be associated with the odds of initiating radiotherapy in multivariable analysis (odds ratio of 0.87 for lowest to highest income level; 95% CI, 0.63-1.20).

CONCLUSIONS

MHI appears to independently predict CSS and overall survival in patients with SCCA. Black race was found to remain a predictor of SCCA survival despite controlling for income. Further study is needed to understand the mechanisms by which socioeconomic inequalities affect cancer care and outcomes. Cancer 2018. © 2018 American Cancer Society.

from Cancer via ola Kala on Inoreader http://ift.tt/2HpgZFZ
via IFTTT

Crosstalk between ovarian cancer cells and macrophages via periostin promotes macrophage recruitment

Abstract

Tumor-associated macrophages (TAMs) contribute to tumor progression, but it is not clear how they are recruited to tumor sites. Here we showed that periostin (POSTN) was present at high levels in ovarian cancer ascetic fluids and was correlated with CD163⁺TAMs. The high POSTN level and macrophage infiltration were inversely associated with relapse-free survival for ovarian cancer patients. In vitro studies showed that co-culture with macrophages significantly increased POSTN production in ovarian cancer cells. Further investigation found that POSTN production in ovarian cancer cells was promoted by TGF-β generated by macrophages. Moreover, siRNA of POSTN and POSTN neutralizing antibody treatment demonstrated that ovarian cancer cell-derived POSTN promoted the recruitment of macrophages and modulated their cytokine secretion profile. Collectively, these data demonstrated that POSTN was an important factor for macrophage recruitment in tumor microenvironment, involved in the interactions between macrophages and ovarian cancer cells.

This article is protected by copyright. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/2p1n5Ws
via IFTTT

Crosstalk between ovarian cancer cells and macrophages via periostin promotes macrophage recruitment

Abstract

Tumor-associated macrophages (TAMs) contribute to tumor progression, but it is not clear how they are recruited to tumor sites. Here we showed that periostin (POSTN) was present at high levels in ovarian cancer ascetic fluids and was correlated with CD163⁺TAMs. The high POSTN level and macrophage infiltration were inversely associated with relapse-free survival for ovarian cancer patients. In vitro studies showed that co-culture with macrophages significantly increased POSTN production in ovarian cancer cells. Further investigation found that POSTN production in ovarian cancer cells was promoted by TGF-β generated by macrophages. Moreover, siRNA of POSTN and POSTN neutralizing antibody treatment demonstrated that ovarian cancer cell-derived POSTN promoted the recruitment of macrophages and modulated their cytokine secretion profile. Collectively, these data demonstrated that POSTN was an important factor for macrophage recruitment in tumor microenvironment, involved in the interactions between macrophages and ovarian cancer cells.

This article is protected by copyright. All rights reserved.

http://ift.tt/2p1n5Ws

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours, Published online: 12 March 2018; doi:10.1038/s41416-018-0003-3

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

http://ift.tt/2FrUfsl

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models, Published online: 12 March 2018; doi:10.1038/s41416-018-0008-y

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models

http://ift.tt/2FGdG05

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts, Published online: 12 March 2018; doi:10.1038/s41416-018-0010-4

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts

http://ift.tt/2tCc8zs

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study, Published online: 12 March 2018; doi:10.1038/s41416-018-0021-1

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

http://ift.tt/2GhL23c

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours, Published online: 12 March 2018; doi:10.1038/s41416-018-0003-3

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

from Cancer via ola Kala on Inoreader http://ift.tt/2FrUfsl
via IFTTT

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models, Published online: 12 March 2018; doi:10.1038/s41416-018-0008-y

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models

from Cancer via ola Kala on Inoreader http://ift.tt/2FGdG05
via IFTTT

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts, Published online: 12 March 2018; doi:10.1038/s41416-018-0010-4

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts

from Cancer via ola Kala on Inoreader http://ift.tt/2tCc8zs
via IFTTT

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study, Published online: 12 March 2018; doi:10.1038/s41416-018-0021-1

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

from Cancer via ola Kala on Inoreader http://ift.tt/2GhL23c
via IFTTT

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer

Opinion statement

Bone health and breast cancer are two connected subjects, because breast cancer patients have a higher prevalence of osteopenia/osteoporosis and reduced bone health parameters than healthy woman of the same age. Therefore, the positive effect of adjuvant bisphosphonate therapy plays an important role in breast cancer treatment. Several randomized trials have studied bisphosphonates in the adjuvant setting in postmenopausal woman and demonstrated their potential to prevent treatment-induced bone loss. The prevention of fractures and the subsequent preservation of patients' quality of life are important arguments for the use of adjuvant bisphosphonates in postmenopausal breast cancer patients. In addition, trials of adjuvant bone-targeted agents showed a reduction of recurrences in and outside bone and an improved outcome in patients treated with bisphosphonates.

from Cancer via ola Kala on Inoreader http://ift.tt/2Hq5jDb
via IFTTT

Testing the Timing: Time Factor in Radiation Treatment for Head and Neck Cancers

Opinion statement

Overall radiation treatment time has long been recognized as an important factor in head and neck tumor control. The concern of tumor growth in waiting time either before starting radiotherapy or during treatment is substantial given its negative impact on clinical outcome. There is an overwhelming evidence that increasing the time to initiate treatment increases the tumor burden and worsens the prognosis. This effect is more pronounced especially in patients with an early stage cancer disease. Delay in treatment initiation is contributed by both health care- and patient-related factors. Health care-related factors include advancement in diagnostic modalities and transfer of patient to academic health care centers accompanied by delayed referrals and long-awaited appointments. Patient-related factors include delayed reporting time and socioeconomic factors. An efficient transition of care along with access of cancer care modalities to community health care centers will not only improve the quality of care in secondary health care centers but also help decrease the patient burden in tertiary centers. A quick and well-structured multidisciplinary appointment program is fundamental in shortening the time required for patient referrals, thus increasing the optimal survival time for Head and Neck cancer patients with early initiation of treatment.

from Cancer via ola Kala on Inoreader http://ift.tt/2FJqiTW
via IFTTT

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer

Opinion statement

Bone health and breast cancer are two connected subjects, because breast cancer patients have a higher prevalence of osteopenia/osteoporosis and reduced bone health parameters than healthy woman of the same age. Therefore, the positive effect of adjuvant bisphosphonate therapy plays an important role in breast cancer treatment. Several randomized trials have studied bisphosphonates in the adjuvant setting in postmenopausal woman and demonstrated their potential to prevent treatment-induced bone loss. The prevention of fractures and the subsequent preservation of patients' quality of life are important arguments for the use of adjuvant bisphosphonates in postmenopausal breast cancer patients. In addition, trials of adjuvant bone-targeted agents showed a reduction of recurrences in and outside bone and an improved outcome in patients treated with bisphosphonates.

http://ift.tt/2Hq5jDb

Testing the Timing: Time Factor in Radiation Treatment for Head and Neck Cancers

Opinion statement

Overall radiation treatment time has long been recognized as an important factor in head and neck tumor control. The concern of tumor growth in waiting time either before starting radiotherapy or during treatment is substantial given its negative impact on clinical outcome. There is an overwhelming evidence that increasing the time to initiate treatment increases the tumor burden and worsens the prognosis. This effect is more pronounced especially in patients with an early stage cancer disease. Delay in treatment initiation is contributed by both health care- and patient-related factors. Health care-related factors include advancement in diagnostic modalities and transfer of patient to academic health care centers accompanied by delayed referrals and long-awaited appointments. Patient-related factors include delayed reporting time and socioeconomic factors. An efficient transition of care along with access of cancer care modalities to community health care centers will not only improve the quality of care in secondary health care centers but also help decrease the patient burden in tertiary centers. A quick and well-structured multidisciplinary appointment program is fundamental in shortening the time required for patient referrals, thus increasing the optimal survival time for Head and Neck cancer patients with early initiation of treatment.

http://ift.tt/2FJqiTW

HOX cluster-embedded micro-RNAs and cancer

Publication date: Available online 11 March 2018
Source:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Author(s): Sebastian Fantini, Valentina Salsi, Vincenzo Zappavigna




http://ift.tt/2Fs8SvL

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models

http://ift.tt/2p7yNOj

Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models

from Cancer via ola Kala on Inoreader http://ift.tt/2p7yNOj
via IFTTT

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

http://ift.tt/2Djq8xF

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts

http://ift.tt/2p1AX2N

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

http://ift.tt/2DiSnwp

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

from Cancer via ola Kala on Inoreader http://ift.tt/2Djq8xF
via IFTTT

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts

from Cancer via ola Kala on Inoreader http://ift.tt/2p1AX2N
via IFTTT

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

from Cancer via ola Kala on Inoreader http://ift.tt/2DiSnwp
via IFTTT

Evaluation of the quality of the reporting of phase II clinical trials in oncology: a systematic review

Publication date: Available online 10 March 2018
Source:Critical Reviews in Oncology/Hematology
Author(s): Romain Rivoirard, Julien Langrand-Escure, Mathieu Oriol, Fabien Tinquaut, Franck Chauvin, Chloé Rancoule, Nicolas Magné, Aurélie Bourmaud
ObjectiveTo describe the current state of knowledge concerning the quality of reporting in phase II clinical trials in oncology and to describe the various methods published allowing this quality evaluation.Methodsdatabases including MEDLINE and COCHRANE were searched. Reviews and meta-analyses analyzing the quality of the reporting of phase II trials in oncology were included. Descriptive analysis of the results was performed.ResultsThirteen publications were retained. Only 2 publications adopted a systematic approach of evaluation of the quality of reporting by overall scores. The Key Methodological Score (KMS), proposed by Grellety et al., gathering 3 items, seemed adapted for such an evaluation. A score of 3/3 was found in 16.1% of the 156 phase II trials analyzed by this score. The other reviews used a qualitative analysis to evaluate the reporting, via an analysis of a single criterion, generally the statistical plan of the study. This item was considered as having been correctly reported in less than 50% of the analyzed articles.ConclusionThe quality of reporting in phase II trials in oncology is a field that has been investigated very little (13 publications). When it is studied, the estimated level of quality is not satisfactory, whatever the method employed. The use of an overall score of evaluation is a path which should be pursued, in order to get reliable results. It also seems necessary to propose strong recommendations, which would create a consensus for the methodology and the reporting of these studies.



http://ift.tt/2Fw0tUd

Evaluation of the quality of the reporting of phase II clinical trials in oncology: a systematic review

Publication date: Available online 10 March 2018
Source:Critical Reviews in Oncology/Hematology
Author(s): Romain Rivoirard, Julien Langrand-Escure, Mathieu Oriol, Fabien Tinquaut, Franck Chauvin, Chloé Rancoule, Nicolas Magné, Aurélie Bourmaud
ObjectiveTo describe the current state of knowledge concerning the quality of reporting in phase II clinical trials in oncology and to describe the various methods published allowing this quality evaluation.Methodsdatabases including MEDLINE and COCHRANE were searched. Reviews and meta-analyses analyzing the quality of the reporting of phase II trials in oncology were included. Descriptive analysis of the results was performed.ResultsThirteen publications were retained. Only 2 publications adopted a systematic approach of evaluation of the quality of reporting by overall scores. The Key Methodological Score (KMS), proposed by Grellety et al., gathering 3 items, seemed adapted for such an evaluation. A score of 3/3 was found in 16.1% of the 156 phase II trials analyzed by this score. The other reviews used a qualitative analysis to evaluate the reporting, via an analysis of a single criterion, generally the statistical plan of the study. This item was considered as having been correctly reported in less than 50% of the analyzed articles.ConclusionThe quality of reporting in phase II trials in oncology is a field that has been investigated very little (13 publications). When it is studied, the estimated level of quality is not satisfactory, whatever the method employed. The use of an overall score of evaluation is a path which should be pursued, in order to get reliable results. It also seems necessary to propose strong recommendations, which would create a consensus for the methodology and the reporting of these studies.



from Cancer via ola Kala on Inoreader http://ift.tt/2Fw0tUd
via IFTTT

Risk Stratification for Melanoma: Models Derived and Validated in a Purpose-Designed Prospective Cohort

Abstract

Background

Risk stratification can improve the efficacy and cost-efficiency of screening programs for early detection of cancer. We sought to derive a risk stratification tool for melanoma that was suitable for the general population using only self-reported information.

Methods

We used melanoma risk factor information collected at baseline from QSKIN, a prospective cohort study of Queensland adults age 40 to 69 years at recruitment (n = 41 954). We examined two separate outcomes: 1) invasive melanomas and 2) all melanomas (invasive + in situ) obtained through data linkage to the cancer registry. We used stepwise Cox proportional hazards modeling to derive the risk models in a randomly selected two-thirds sample of the data set and assessed model performance in the remaining one-third validation sample.

Results

After a median follow-up of 3.4 years, 655 (1.6%) participants developed melanoma (257 invasive, 398 in situ). The prediction model for invasive melanoma included seven terms. At baseline, the strongest predictors of invasive melanoma were age, sex, tanning ability, number of moles at age 21 years, and number of skin lesions treated destructively. The model for "all melanomas" (ie, invasive and in situ) included five additional terms. Discrimination in the validation data set was high for both models (C-index = 0.69, 95% confidence interval [CI] = 0.62 to 0.76, and C-index = 0.72, 95% CI = 0.69 to 0.75, respectively), and calibration was acceptable.

Conclusions

Such a tool could be used to target surveillance activities to those at highest predicted risk of developing melanoma over a median duration of 3.4 years.

http://ift.tt/2IhuvNm

Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature

Chronic lymphocytic leukemia and chronic myeloid leukemia are the most common types of adult leukemia. However, it is rare for the same patient to suffer from both. Richter's transformation to diffuse large B-...

http://ift.tt/2p1vSaL

Literature Review of Spinal Cord Glioblastoma

Objectives: This systematic review aims to investigate spinal cord glioblastoma (scGBM) and correlations between patient traits and survival outcome, as well as differences in cohorts administered temozolomide or total resections, through an analysis of published cases reported up to October 2016. Methods: We obtained patient data by querying PubMed and Google Scholar with predetermined search terms and inclusion criteria that enabled the identification of relevant case reports. Survival was compared using Kaplan-Meier curves and log-rank analyses. Results: Of 153 patients with scGBM identified through a literature search, 135 met the predetermined search and inclusion criteria. Median overall survival (OS) for the resulting cohort was 12 (95% CI, 10-14) months. The female sex was found to significantly predict worse outcomes, and a sizable number of patients with long-term disease were found to have afflictions of the thoracic spinal cord. Neither the pediatric, temozolomide nor total resection subgroups had significantly improved survival characteristics, by log-rank analysis, relative to counterparts. Conclusions: These data elucidate the characteristics of patients with scGBM. For more sophisticated and in-depth analyses in the future, it is imperative that time-of-treatment information is recorded in future case reports. In addition, all case reports should be made available to prevent publication bias. J.J.T. and K.Z. contributed equally. Present address: Shiva Gautam, PhD, Department of Biostatistics, University of Florida College of Medicine Jacksonville, Jacksonville, FL. Supported in part by A Reason to Ride research fund. J.J.T.: study concept and design, acquisition of data, analysis and interpretation and critical revision of manuscript for intellectual content. K.Z., J.F., E.L.: acquisition of data, analysis, and interpretation. K.D.S.: analysis and interpretation, and critical revision of manuscript for intellectual content. S.G.: analysis and interpretation. E.T.W.: study concept and design, acquisition of data, analysis and interpretation, study supervision and critical revision of manuscript for intellectual content. E.T.W.: received research support from AstraZeneca, Cephalon, Eli Lilly, Northwest Biotherapeutics, Novartis, Novocure, Pfizer, Plexxicon, and Tocagen. K.D.S.: received research support from Novocure and Tocagen. The remaining authors declare that they have nothing to disclose. Reprints: Eric T. Wong, MD, Brain Tumor Center & Neuro-Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. E-mail: ewong@bidmc.harvard.edu. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

http://ift.tt/2DiDtpQ

Literature Review of Spinal Cord Glioblastoma

Objectives: This systematic review aims to investigate spinal cord glioblastoma (scGBM) and correlations between patient traits and survival outcome, as well as differences in cohorts administered temozolomide or total resections, through an analysis of published cases reported up to October 2016. Methods: We obtained patient data by querying PubMed and Google Scholar with predetermined search terms and inclusion criteria that enabled the identification of relevant case reports. Survival was compared using Kaplan-Meier curves and log-rank analyses. Results: Of 153 patients with scGBM identified through a literature search, 135 met the predetermined search and inclusion criteria. Median overall survival (OS) for the resulting cohort was 12 (95% CI, 10-14) months. The female sex was found to significantly predict worse outcomes, and a sizable number of patients with long-term disease were found to have afflictions of the thoracic spinal cord. Neither the pediatric, temozolomide nor total resection subgroups had significantly improved survival characteristics, by log-rank analysis, relative to counterparts. Conclusions: These data elucidate the characteristics of patients with scGBM. For more sophisticated and in-depth analyses in the future, it is imperative that time-of-treatment information is recorded in future case reports. In addition, all case reports should be made available to prevent publication bias. J.J.T. and K.Z. contributed equally. Present address: Shiva Gautam, PhD, Department of Biostatistics, University of Florida College of Medicine Jacksonville, Jacksonville, FL. Supported in part by A Reason to Ride research fund. J.J.T.: study concept and design, acquisition of data, analysis and interpretation and critical revision of manuscript for intellectual content. K.Z., J.F., E.L.: acquisition of data, analysis, and interpretation. K.D.S.: analysis and interpretation, and critical revision of manuscript for intellectual content. S.G.: analysis and interpretation. E.T.W.: study concept and design, acquisition of data, analysis and interpretation, study supervision and critical revision of manuscript for intellectual content. E.T.W.: received research support from AstraZeneca, Cephalon, Eli Lilly, Northwest Biotherapeutics, Novartis, Novocure, Pfizer, Plexxicon, and Tocagen. K.D.S.: received research support from Novocure and Tocagen. The remaining authors declare that they have nothing to disclose. Reprints: Eric T. Wong, MD, Brain Tumor Center & Neuro-Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. E-mail: ewong@bidmc.harvard.edu. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/2DiDtpQ
via IFTTT